Voluntary nationwide recall: Duloxetine (Towa – October)

Dec. 2024Pharmacy Updates

Towa Pharmaceutical is recalling one lot, lot 220128, of Duloxetine Delayed-Release Capsules, USP, 20 mg. Duloxetine is used to treat anxiety, depression, and certain types of nerve pain.

This drug is being recalled because it contained an impurity called N-nitroso-duloxetine. According to the FDA, nitrosamine impurities may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time. Additionally, the FDA added that someone who is taking a drug that contains nitrosamines at or below the acceptable daily intake limits every day for several years is not expected to have an increased risk of cancer.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA report and website below. If you have an affected lot of Duloxetine, The FDA advises that you should stop using the product and return it to the place of purchase or throw it away.

As of Oct. 23, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

Recent Announcements

CME Webinar: American Foundation for Suicide Prevention’s ‘Talk Saves Lives’ Program

Please join us on Tuesday, April 28, from noon to 1 p.m. for “Talk Saves Lives: An Introduction to Suicide Prevention.” This live, CME-accredited webinar is the American Foundation for Suicide Prevention’s flagship suicide prevention education program. It covers the scope of this leading cause of death, warning signs and risk factors for suicide, and strategies to prevent it.
Feb. 2026Education/Webinars

Training Webinar: Conversio Health COPD Management Program

Please join us for a live training webinar by UPMC Health Plan that will provide an overview of a comprehensive COPD management program from Conversio Health.
Jan. 2026Education/Webinars

Provider Directory Updates and Required Attestation

As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).
Jan. 2026Important Notices